Clinical Trial Update: Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL) [Phase 2]

View source ↗

Summary

Phase 2 study of Fc-optimized anti-CD19 antibody MOR00208 for B-cell acute lymphoblastic leukemia has been terminated; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• MOR00208

Snippet

Sponsor: MorphoSys AG | Conditions: Acute Lymphoblastic Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2018-02-22